Vertex Pharmaceuticals
VRTX
856 hedge funds and large institutions have $58.4B invested in Vertex Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 135 funds opening new positions, 331 increasing their positions, 275 reducing their positions, and 86 closing their positions.
78% more funds holding in top 10
Funds holding in top 10: 18 → 32 (+14)
57% more first-time investments, than exits
New positions opened: 135 | Existing positions closed: 86
20% more repeat investments, than reductions
Existing positions increased: 331 | Existing positions reduced: 275
16% more call options, than puts
Call options by funds: $306M | Put options by funds: $264M
9% more capital invested
Capital invested by funds: $53.4B → $58.4B (+$4.96B)
5% more funds holding
Funds holding: 814 → 856 (+42)
0.2% less ownership
Funds ownership: 94.94% → 94.74% (-0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$455M |
| 2 |
BlackRock
New York
|
+$277M |
| 3 |
Jennison Associates
New York
|
+$181M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$161M |
| 5 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$145M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$666M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$276M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$134M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$122M |
| 5 |
SIG
Senator Investment Group
New York
|
-$98.5M |
VRTX Hedge Fund Activity: Q1 2020 in Review
856 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2020, worth a combined $58.4B — up 9.3% from $53.4B a quarter earlier.
Buyers outnumbered sellers: 135 funds opened new VRTX positions and 86 closed out — a net gain of 49 holders — while 331 added to existing stakes and 275 trimmed.
The largest buyer was Capital World Investors, adding an estimated $455M. The largest seller was T. Rowe Price Associates, cutting an estimated $666M.
- 856 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2020, up from 814 in Q4 2019.
- Funds reported $58.4B of Vertex Pharmaceuticals stock for Q1 2020, up 9.3% quarter-over-quarter.
- 135 funds opened new Vertex Pharmaceuticals positions in Q1 2020 and 86 closed out, a net change of +49 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2020 was Capital World Investors, an estimated $455M added.
- The largest Vertex Pharmaceuticals seller in Q1 2020 was T. Rowe Price Associates, an estimated $666M sold.
Based on aggregated 13F filings for Q1 2020.